Evaluating the use of new tumor measurement tools for studies of molecular-targeted cancer therapies.
Why the requirement for the collection of cardiac safety data?
With this technology in place, INC may be able to eliminate the need for a separate, dedicated Thorough QT (TQT) studies.
INTERLAB and synlab have been successfully cooperating since 2004.
Tufts CSDD finds drug and diagnostics companies are investing in the development of companion diagnostics that can show that their use in conjunction with personalized therapeutics will lead to positive health outcomes.
The Jumpstarting Brain Tumor Drug Development Coalition (JBTDDC) announced a new consensus protocol for magnetic resonance imaging (MRI) in brain tumor clinical trials to help assess if a new treatment is effective.
Applied Clinical Trials discusses acquisition with iCardiac CEO Alex Zapesochny.